triumph 1 retatrutide produces up to 30.3% weight loss in Phase 3 trial Retatrutide Achieves Up to 30.3%

found that both UC and CD patients with DM2 presented a reduced risk of surgery when treated with GLP-1 RAs compared to other hypoglycemic agents (97)

GLP-1 receptor agonists, such as exenatide, help protect the ovarian and endometrial environments from oxidative stress, fibrosis, and chronic inflammation

Your healthcare provider will start these weight loss injections on the lower dose (0.25 mg weekly) and gradually increase the dose based on how you respond, your goals, and your tolerance for side effects

Blood sugar improvements most likely to be measurable in people with elevated baseline levels

The 5R Framework: 1

Seven central nervous system and addiction indications